Skip to search formSkip to main contentSkip to account menu

EW-7197

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 3186: A novel combination therapy for treating advanced drug resistant acute lymphoblastic leukemia
Purpose: Drug resistance and relapse are two major problems in Acute Lymphoblastic Leukemia (ALL) as these patients do not… 
2016
2016
The mechanistic study of EW-7197, an activin like kinase 5 (ALK5) inhibitor, in cholestatic liver fibrosis
Highly Cited
2015
Highly Cited
2015
Combinatorial TGF-β attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells
Distant relapse after chemotherapy is an important clinical issue for treating breast cancer patients and results from the… 
2014
2014
Safety evaluation of a novel TβRI/ALK5 inhibitor EW-7197
2013
2013
Abstract 3237: Combination therapy of paclitaxel and EW-7197, a novel ALK5 inhibitor prolonged the life span of breast tumor bearing mice.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC TGF-β has multifunctional effects on carcinogenesis… 
2012
2012
Abstract 1918: Anti-metastasis effect of EW-7197, a novel ALK5 inhibitor in both breast cancer cellsin vitroand mouse modelin vivo
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL We have synthesized new ALK5 inhibitor, EW-7197… 
2012
2012
EW-7197 and Paclitaxel Combination Therapy Prolonged the Life Span of Breast Tumor Bearing Mice
2011
2011
Application of HPLC methods for determination of EW-7197 and its salt in rat plasma and comparison of their pharmacokinetics
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)